Sign in

    Mal Ramesh • Sudetsky

    Mal Ramesh is a Vice President and Equity Research Analyst at Sudetsky, specializing in healthcare and biotechnology sectors with a focus on mid-cap pharmaceutical and life sciences companies. He covers firms such as BioMarin Pharmaceutical, Alnylam Pharmaceuticals, and Vertex Pharmaceuticals, earning recognition for a success rate of 65% and an average annualized return of 13% on his published investment theses. Ramesh began his finance career in 2013 at Cowen Group as a healthcare associate, later advancing to Evercore ISI and joining Sudetsky in 2021. He holds FINRA Series 7 and 63 licenses and has been highlighted by industry platforms for comprehensive pipeline analysis and accurate earnings forecasts.

    Mal Ramesh's questions to Yatra Online Inc (YTRA) leadership

    Mal Ramesh's questions to Yatra Online Inc (YTRA) leadership • Q1 2026

    Question

    Mal Ramesh from Sudetsky questioned the company's 9% gross booking growth relative to the market, the current business mix between corporate and consumer travel, and the potential cost savings from the ongoing corporate restructuring.

    Answer

    Co-Founder & CEO Dhruv Shringi explained that the modest booking growth was a weighted average, with strong corporate performance offset by a macro-impacted decline in the consumer segment. He confirmed the business mix remains roughly two-thirds corporate. Shringi also stated the restructuring will yield savings, including an estimated $5 million in annual tax savings.

    Ask Fintool Equity Research AI